including POM3 treatment, in patients with hypertriglyceridemia. Moreover, results from clinical event trials are needed to assess the risks and benefits of combinations of lipid-altering ...

Currently, it is being evaluated in three Phase III clinical trials – CORE, CORE2, and ESSENCE – for the treatment of severe hypertriglyceridemia, although it has not yet been reviewed or ...

Am J Health Syst Pharm. 2007;64(6):595-605. Perhaps a more important issue, especially with regard to the size of the affected population, is the efficacy of P-O3FA in reducing non-HDL cholesterol ...

Pegozafermin For The Treatment Of Patients With Severe Hypertriglyceridemia As I noted above, 89bio is in the process of also exploring the use of its FGF21 analog for the treatment of patients ...

Considering taking supplements to treat hypertriglyceridemia? Below is a list of common natural remedies used to treat or reduce the symptoms of hypertriglyceridemia. Follow the links to read ...

Q1 2025 Management View CEO Chris Anzalone announced the closure of a significant licensing and collaboration agreement with Sarepta Therapeutics, which will provide $1.375 billion in upfront and near ...

for plozasiran for the treatment for familial chylomicronemia syndrome (FCS). In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe ...

As of October 2022, Vascepa had coverage without restrictions for more than 90% of Medicare Part D enrollees, according to its manufacturer. According to Optum Perks, 30 capsules of Vascepa cost as ...

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...